{"contentid": 488618, "importid": NaN, "name": "Curis rockets on release of data for CA-4948 in AML and MDS", "introduction": "Shares of oncology focussed US biotech firm Curis closed up 65.5% at $16.27 yesterday, after it announced that two abstracts for CA-4948, a novel, small molecule IRAK4 inhibitor, have been accepted for oral and poster presentation at the European Hematology Association 2021 Virtual Congress (EHA), which will be held virtually June 9-17, 2021.", "content": "<p>Shares of oncology focussed US biotech firm Curis (Nasdaq: CRIS) closed up 65.5% at $16.27 yesterday, after it announced that two abstracts for CA-4948, a novel, small molecule IRAK4 inhibitor, have been accepted for oral and poster presentation at the European Hematology Association 2021 Virtual Congress (EHA), which will be held virtually June 9-17, 2021.</p>\n<p>The abstracts include updated data from a February data-cut for its ongoing open-label, single arm, Phase I/II study of CA-4948 in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS).</p>\n<p>\"We are very pleased to report this clinical update on our first-in-class IRAK4 kinase inhibitor, CA-4948, as an anticancer agent for&nbsp;patients with acute myeloid leukemia and myelodysplastic syndromes for whom multiple prior lines of therapy have been unsuccessful,\" said James Dentzer, president and chief executive of Curis.</p>\n<p>\"The clinical data published in the abstract this morning are consistent with our preliminary findings reported late last year showing that CA-4948 has, in addition to encouraging safety characteristics, clear potential to reduce leukemic blasts in late-line patients, along with early signs of hematologic recovery. We look forward to providing updated safety, pharmacodynamic, and efficacy data, as well as data from additional patients and non-clinical combination synergy data at EHA next month.\" &nbsp;</p>\n<h2><strong>Key findings of the study</strong></h2>\n<p>Key findings from a cut-off date of February 8, 2021&nbsp;in 15 patients (8 MDS and 7 AML) include:</p>\n<ul>\n<li>Bone marrow blast reductions observed at all tested doses in eight of nine (89%) evaluable patients (at least one malignancy assessment following first cycle) with elevated blast counts at baseline;</li>\n<li>Objective responses observed included one patient experiencing a full hematologic recovery complete response, 1 CRi with negative minimal residual disease, and 2 bone marrow CRs;</li>\n<li>All three patients with SF3B1 or U2AF1 spliceosome mutation achieved marrow CR or better; and</li>\n<li>All patients with objective responses also saw signs of hematologic recovery.</li>\n</ul>", "date": "2021-05-13 11:30:00", "meta_title": "Curis rockets on release of data for CA-4948 in AML and MDS", "meta_keywords": "Curis, CA-4948, Phase I/II, Myeloid leukemia, AML,  Myelodysplastic syndromes, MDS, EHA meeting", "meta_description": "Curis rockets on release of data for CA-4948 in AML and MDS", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-13 11:29:20", "updated": "2021-05-14 17:26:15", "access": NaN, "url": "https://www.thepharmaletter.com/article/curis-rockets-on-release-of-data-for-ca-4948-in-aml-and-mds", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "curis_large.png", "image2id": "curis_small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": "AML, MDS", "sector_tag": "Biotechnology", "therapy area_tag": "Hematology, Oncology", "topic_tag": "Conferences, Drug Trial, Research", "geography_tag": "USA", "company_tag": "Curis", "drug_tag": "CA-4948", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-13 11:30:00"}